Orforglipron
Orforglipron (Fandanyo) is a non-peptide, oral GLP-1 receptor agonist approved by the FDA. Unlike oral semaglutide (a peptide requiring fasting), orforglipron is a small molecule that can be taken without food restrictions, making GLP-1 therapy accessible to injection-averse and fasting-intolerant patients.
Evidence Summary
FDA approved in January 2025 (brand name Fandanyo). ACHIEVE-1 (n=1,632), ACHIEVE-2 (n=1,576), and ACHIEVE-3 (n=1,400) Phase 3 trials demonstrated robust HbA1c reductions, significant weight loss, and a cardiovascular outcomes trial (ATTAIN) is ongoing. Real-world use confirms oral bioavailability without food restrictions, establishing it as a first-line oral GLP-1 receptor agonist option.
Evidence Scale
Mechanism of Action
Non-peptide small molecule GLP-1 receptor agonist. Binds to and activates GLP-1 receptors with similar downstream effects as peptide GLP-1 RAs (insulin secretion, appetite suppression, gastric slowing) but without the bioavailability limitations of oral peptides. No fasting requirement for absorption.
Who Is This For?
Type 2 diabetes, obesity/overweight with comorbidities. Ideal for injection-averse patients and those who cannot tolerate peptide GLP-1 RAs. Suitable as first-line oral GLP-1 option.
Protocol & Dosing
Dose
3 mg, 12 mg, 24 mg, and 36 mg daily oral tablets (approved doses). Taken once daily with or without food. No fasting required. Titration typically starts at 3 mg, with dose increases every 4 weeks based on tolerance and clinical response.
Frequency
Daily oral tablet (with or without food)
Duration
Chronic / maintenance (long-term use)
Protocol Summary
First and only FDA-approved non-peptide oral GLP-1 receptor agonist. Eliminates injection requirement and fasting restrictions of oral semaglutide. Prescribed for type 2 diabetes and weight management.
Interactions & Precautions
Contraindications
- Not fully established
- Likely similar to GLP-1 RA class warnings
Potential Risks
- •Long-term safety data pending
- •Oral bioavailability in real-world conditions unknown
- •Drug interaction profile not fully characterized
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Now FDA-approved as Fandanyo. First non-peptide oral GLP-1 RA eliminating both injection requirement and fasting restrictions of oral semaglutide. Monitor for GI side effects during titration. Drug-drug interaction profile better characterized post-approval. Consider as oral alternative when injectable GLP-1 RAs are declined.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Purchase Oral GLP-1
Orforglipron capsules available in 3 mg and 12 mg through Peak Human Shop.
Cost & Access
Cost Range
TBD
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation